Dr. Haisheng Zhang is the Founder and CEO of Signet Therapeutics. He also serves as the Director of the Cancer Targeted Therapy Research Center at the Tsinghua Shenzhen International Graduate School and is an adjunct professor at Southern Medical University Nanfang Hospital.

Dr. Zhang completed his postdoctoral research at the Dana-Farber Cancer Institute (DFCI), Harvard University, and was a research fellow at the Broad Institute of MIT and Harvard. His research focuses on targeted therapies and companion diagnostics for gastric cancer. As the first author, he published his research in Cancer Discovery (IF 39.4), identifying FAK as a key target in diffuse gastric cancer (DGC) and elucidating its underlying mechanisms. Building on this discovery, he founded Signet Therapeutics to develop SIGX1094, the world’s first targeted therapy for DGC and other cancers, which has now entered Phase I clinical trials.

Adam Bass, MD is a physician-scientist who has studied the genomic underpinning of gastric and esophageal cancer and subsequently performed functional genomic studies to define the biological bases and molecular vulnerabilities in these cancers.  Following a decade on the faculty of the Dana-Farber Cancer Institute he is now the Global Head of Oncology Translational Research at Novartis Institutes for BioMedical Research.